Articles

If you build it, they will come

Vetter to invest $320 million in manufacturing plant
Written byLori Lesko
| 3 min read

RAVENSBURG, Germany—Taking a huge step toward expanding its global footprint, German biopharmaceutical company Vetter stands poised to pour $320 million into the development of 18 acres in Des Plaines, Ill., for the construction of a 1.2 million-square-foot manufacturing plant, the German company’s second and largest U.S. site, thus strengthening its strategic partnership plan. Vetter’s economic development agreement with the state of Illinois is expected to create up to 500 jobs designed to meet the market supply needs of commercialized drugs by 2030. Although the deal, forged July 12, appears to be a go, final approval rests with Des Plaines City Council.

If the project goes as planned, the new facility would complement Vetter’s existing site at the Illinois Science+Technology Park in nearby Skokie, Ill., which has approximately 70 employees.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Researcher examining a multiwell plate alongside cell culture dishes in a laboratory.
Explore how direct cell lysis can reduce sample preparation steps and support efficient gene expression analysis by RT-qPCR.
Abstract rainbow-colored beams of light spreading across a dark background.
Compare fluorochromes based on resolution, spillover, antigen expression, and other factors that can affect panel performance.
Illustration of multiple glowing blue and purple spherical cells against a dark blue background.
As researchers embrace more complex cellular models, high-content analysis brings new opportunities and challenges to drug discovery.